

Date Mailed: OCTOBER 1, 2003

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b> (Use several sheets if necessary)	Docket Number:	Application Number:
	11669.132USC1	09/520,130
	Applicant: ARATHOON ET AL.	
	Filing Date: MARCH 7, 2000	Group Art Unit: 1642
Customer No. 23552		

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
ALH	5,731,168	03/1998	CARTER ET AL.			
ALH	5,821,333	10/1998	CARTER ET AL.			

  

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

  

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
ALH		Bedzyk et al., "Active Site Structure and Antigen Binding Properties of Idiotypically Cross-reactive Anti-fluorescein Monoclonal Antibodies", <u>The Journal of Biological Chemistry</u> , 265(1):133-138 (1990)
ALH		Bryunck, A. et al., "Characterisation of a humanized bispecific monoclonal antibody for cancer therapy", <u>Br. J. Cancer</u> , 67:436-440 (1993)
ALH		Carter, P. et al., "Toward The Production of Bispecific Antibody Fragments for Clinical Applications", <u>J. Hematotherapy</u> , 4(5):463-470 (Oct. 1995)
ALH		Carter, P. et al., "Engineering antibodies for imaging and therapy", <u>Curr. Opin. Biotechnology</u> , 8(4):449-454 (Aug. 1997)
ALH		De Jonge, J. et al., "Production and Characterization of Bispecific Single-Chain Antibody Fragments", <u>Mol. Immunol.</u> , 32(17-18):1405-1412 (Dec. 1995)
ALH		Goddard et al., NCBI Genbank AF048774 (1998)
ALH		Goddard et al., NCBI Genbank AF048775 (1998)
ALH		Gulliver, G. et al., "Conversion of an Anti-single-stranded DNA Active Site to an Anti-fluorescein Active Site through Heavy Chain Complementarity Determining Region Transplantation", <u>The Journal of Biological Chemistry</u> , 269(11):7934-7940 (1994)
ALH		Gulliver, G. et al., "Effect of Transplantation of Antibody Heavy Chain Complementarity Determining Regions on Ligand Binding", <u>The Journal of Biological Chemistry</u> , 269(39):24040-24045 (Sept. 30, 1994)
ALH		Kriangkum, J. et al., "Bispecific and bifunctional single chain recombinant antibodies", <u>Biomolecular Engineering</u> , 18(1):31-40 (Aug. 2001)

EXAMINER	<i>Anne L. Holleran</i>	DATE CONSIDERED	3/22/04
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.			

\*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Date Mailed: OCTOBER 1, 2003

<b>FORM 1449*</b> <b>INFORMATION DISCLOSURE STATEMENT</b>  <b>IN AN APPLICATION</b> (Use several sheets if necessary)	Docket Number: 11669.132USC1	Application Number: 09/520,130
	Applicant: ARATHOON ET AL.	
	Filing Date: MARCH 7, 2000	Group Art Unit: 1642
	Customer No. 23552	

ArH	Mallender, W. et al., "Comparative Properties of the Single Chain Antibody and Fv Derivatives of mAb 4-4-20", <u>The Journal of Biological Chemistry</u> , 271(10):5338-5346 (March 8, 1996)
ArH	Mallender, W. et al., "Construction, Expression, and Activity of a Bivalent Bispecific Single-chain Antibody", <u>The Journal of Biological Chemistry</u> , 269(1):199-206 (Jan. 7, 1994)
ArH	Massino et al., "Quantitative analysis of the products of IgG chain recombination in hybrid hybridomas based on affinity chromatography and radioimmunoassay", <u>Journal of Immunological Methods</u> , 201:57-66 (1997)
ArH	Merchant et al., "An efficient route to human bispecific IgG", <u>Nature Biotechnology</u> , 16:677-681 (July 1998)
ArH	Muller, KM et al., "The first constant domain (C <sub>H</sub> 1 and C <sub>L</sub> ) of an antibody used as heterodimerization domain for bispecific miniantibodies", <u>FEBS Letter</u> , 422(2):259-264 (January 30, 1998)
ArH	Muller, KM et al., "A dimeric bispecific miniantibody combines two specificities with avidity", <u>FEBS Letter</u> , 432(1-2):45-49 (July 31, 1998)
ArH	Pluckthun, A. et al., "New protein engineering approaches to multivalent and bispecific antibody fragments", <u>Immunotechnology</u> , 3(2):83-105 (June 1997)
ArH	Reddy, V. et al., "Production of Hybrids Secreting Bispecific Antibodies Recognising CEA and Doxorubicin", <u>Anticancer Research</u> , 13:2077-2084 (1993)
ArH	Segal, DM et al., "Introduction: bispecific antibodies", <u>J. Immunol. Methods</u> , 248(1-2):1-6 (Feb. 1, 2001)
ArH	Smith et al., "Variable Region Primary Structures of Monoclonal Anti-DNA Autoantibodies from NZB/NZW F <sub>1</sub> Mice", <u>Molecular Immunology</u> , 27(5):463-470 (1990)
ArH	Tomlinson, IM et al., "The structural repertoire of the human V <sub>K</sub> domain", <u>EMBO Journal</u> , 14(18):4628-4638 (Sept. 15, 1995)
ArH	Tomlinson, I. et al., "Methods for Generating Multivalent and Bispecific Antibody Fragments", <u>Methods Enzymol.</u> , 326:461-479 (2000)
ArH	Tso, JY et al., "Preparation of a Bispecific F(ab') <sub>2</sub> Targeted to the Human IL-2 Receptor", <u>J. Hematotherapy</u> , 4(5):389-394 (Oct. 1995)
ArH	Vuillez, J. et al., "Two-Step Immunoscintigraphy for Non-Small-Cell Lung Cancer Staging Using a Bispecific Anti-CEA/Anti-Indium-DTPA Antibody and an Indium-111-Labeled DTPA Dimer", <u>The Journal of Nuclear Medicine</u> , 38(4):507-511 (April 1997)

EXAMINER <i>Anne L. Sullivan</i>	DATE CONSIDERED <i>3/22/04</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

\*Substitute Disclosure Statement Form (PTO-1449)

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE